Enliven Therapeutics Inc. - Asset Resilience Ratio
Enliven Therapeutics Inc. (ELVN) has an Asset Resilience Ratio of 68.89% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read ELVN total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2025)
This chart shows how Enliven Therapeutics Inc.'s Asset Resilience Ratio has changed over time. See shareholders equity of Enliven Therapeutics Inc. for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Enliven Therapeutics Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ELVN market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $320.22 Million | 68.89% |
| Total Liquid Assets | $320.22 Million | 68.89% |
Asset Resilience Insights
- Very High Liquidity: Enliven Therapeutics Inc. maintains exceptional liquid asset reserves at 68.89% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Enliven Therapeutics Inc. Industry Peers by Asset Resilience Ratio
Compare Enliven Therapeutics Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 43.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Shanghai Junshi Biosciences Co Ltd
SHG:688180 |
Biotechnology | 4.28% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
|
Jade Biosciences, Inc.
NASDAQ:JBIO |
Biotechnology | 80.21% |
|
Theravance Biopharma Inc
F:0TB |
Biotechnology | 37.29% |
Annual Asset Resilience Ratio for Enliven Therapeutics Inc. (2019–2025)
The table below shows the annual Asset Resilience Ratio data for Enliven Therapeutics Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 76.39% | $363.73 Million | $476.17 Million | +18.27pp |
| 2024-12-31 | 58.12% | $189.32 Million | $325.76 Million | +1.84pp |
| 2023-12-31 | 56.28% | $153.01 Million | $271.87 Million | -- |
| 2022-12-31 | 0.00% | $0.00 | $83.30 Million | -- |
| 2021-12-31 | 37.03% | $41.97 Million | $113.33 Million | -7.58pp |
| 2020-12-31 | 44.61% | $40.52 Million | $90.84 Million | -27.38pp |
| 2019-12-31 | 71.99% | $23.97 Million | $33.30 Million | -- |
About Enliven Therapeutics Inc.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversibl… Read more